Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
buspirone + levodopa + carbidopa
- Development stage
- Unknown
- Lead developer
- Nordic Life Science Pipeline
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SPINALON (buspirone + levodopa + carbidopa) is a combination therapy being developed by Nordic Life Science Pipeline Inc. for the treatment of chronic spinal cord injury (SCI). It is designed as a Central Pattern Generator (CPG) activator to induce locomotor movements. The therapy combines buspirone, a 5-HT1A receptor agonist, with levodopa and carbidopa to increase spinal levels of serotonin and dopamine, respectively. These monoamine neurotransmitters are typically depleted below the level of injury in SCI patients, and their restoration is intended to increase the excitability of spinal motor neurons and interneurons, potentially enhancing the efficacy of epidural electrical stimulation (EES) and locomotor training.
- Brand names
- SPINALON
- Other names
- buspirone + levodopa-carbidopalevodopa + carbidopa + buspirone
02
Targets
DRD2 (Dopamine D2 Receptor)DDC (Aromatic L-amino acid decarboxylase)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))
Beyond the preview
Go deeper on buspirone + levodopa + carbidopa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on buspirone + levodopa + carbidopa.